Breast cancer metastatic – Diagnostics – Overview of Information and Clinical Research

Diagnosing metastatic breast cancer involves a combination of imaging tests, biopsies, and laboratory analyses to confirm that cancer has spread beyond the breast to other parts of the body. Early detection of metastases and understanding their location and characteristics helps doctors create the most effective treatment plan for each patient.

Introduction: Who Should Undergo Diagnostics

Anyone who has previously been treated for breast cancer should remain alert to new symptoms that could signal the cancer has returned and spread to distant organs. This is especially important because metastatic breast cancer, also called stage IV or advanced breast cancer, often develops months or even years after the original diagnosis and treatment. According to available data, approximately 20% to 30% of women with early-stage breast cancer later develop metastatic disease.^[2]

However, not everyone with metastatic breast cancer has a history of the disease. About 6% to 10% of people receive a metastatic breast cancer diagnosis when they are first diagnosed with breast cancer. This is called de novo metastatic breast cancer, meaning the cancer had already spread to other parts of the body at the time of initial discovery.^[2]^[3]

People who notice persistent, unexplained symptoms should seek medical evaluation promptly. These symptoms might include bone pain that doesn’t go away, ongoing fatigue, shortness of breath, persistent cough, abdominal discomfort, frequent headaches, or weight loss without trying. While these symptoms can be caused by many conditions unrelated to cancer, they deserve medical attention, particularly in anyone who has had breast cancer before.^[2]^[3]

Women who have completed treatment for earlier stages of breast cancer typically undergo regular follow-up appointments with their doctors. During these visits, healthcare providers watch for signs of recurrence. If concerning symptoms appear between scheduled appointments, or if physical examinations or routine tests raise suspicion, further diagnostic workup becomes necessary.^[10]

⚠️ Important

Not every change in how you feel means breast cancer is getting worse or spreading. For instance, fatigue is both a common symptom of metastatic cancer and a side effect of treatments like chemotherapy and radiation. Always talk to your healthcare provider about new or worsening symptoms so they can determine whether diagnostic tests are needed.^[2]

It’s also important to understand that people diagnosed with metastatic breast cancer should undergo specific diagnostic tests even if they feel well at the time. This is because some metastases may not cause noticeable symptoms right away. Proper diagnosis through testing helps doctors understand the full extent of the disease and plan the most appropriate treatment.^[4]

Classic Diagnostic Methods for Identifying Metastatic Breast Cancer

When doctors suspect that breast cancer has spread to other parts of the body, they use a variety of diagnostic tests to confirm the presence of metastases and determine where the cancer has traveled. These tests help distinguish metastatic breast cancer from other conditions that might cause similar symptoms.

Biopsy: The Gold Standard for Confirmation

A biopsy remains one of the most important diagnostic procedures for confirming metastatic breast cancer. During a biopsy, a doctor removes a small sample of tissue from a suspicious area to examine it under a microscope. This is particularly valuable when someone has been cancer-free for a long time, because the biopsy can confirm whether a new growth is actually breast cancer that has returned or something else entirely, such as a benign condition or even a different type of cancer.^[10]

The tissue obtained through biopsy serves multiple purposes beyond simple confirmation. Laboratory specialists can test the sample for specific characteristics of the cancer cells, including hormone receptors (proteins that respond to estrogen or progesterone) and HER2 status (a protein that promotes cancer cell growth). These characteristics may have changed since the original breast cancer was treated, and knowing the current status helps doctors select the most effective treatments.^[10]

Imaging Tests to Locate and Assess Metastases

Imaging tests create detailed pictures of the inside of the body and are essential for finding metastases and understanding how far the cancer has spread. Different imaging techniques are used depending on which organs or body systems doctors need to examine.

Computed Tomography (CT) scans use X-rays taken from multiple angles to create cross-sectional images of the body. CT scans are commonly used to check the chest, abdomen, and pelvis for metastases in the lungs, liver, and other internal organs. The machine rotates around the patient while they lie still on a table, and the entire process is painless, though some people may need to drink or receive an injection of contrast dye to make certain tissues show up more clearly.^[2]

Magnetic Resonance Imaging (MRI) uses powerful magnets and radio waves instead of X-rays to create detailed images of soft tissues. MRI is particularly useful for examining the brain and spinal cord, where breast cancer sometimes spreads. The test requires lying inside a tube-shaped machine for 30 to 60 minutes, and some people find the enclosed space and loud noises challenging, though earplugs and sedation can help.^[2]

Positron Emission Tomography (PET) scans involve injecting a small amount of radioactive sugar into the bloodstream. Cancer cells, which grow rapidly and consume more energy than normal cells, absorb more of this radioactive sugar. The PET scanner then detects areas where the radioactive material has concentrated, highlighting potential sites of cancer throughout the body. PET scans are often combined with CT scans to provide both functional and structural information.^[2]

Bone scans are specifically used to check whether breast cancer has spread to the bones, which is one of the most common sites of metastasis. This test also involves injecting a small amount of radioactive material, but one that collects in areas of bone where cells are breaking down and rebuilding at an abnormal rate. Breast cancer in the bones often shows up as “hot spots” on the scan. Roughly 70% of people living with advanced breast cancer have bone metastases.^[6]

Chest X-rays provide a simple, quick way to look for abnormalities in the lungs. While less detailed than CT scans, they can reveal larger tumors or fluid buildup around the lungs that might indicate metastatic disease.^[10]

Ultrasound uses sound waves to create images of internal organs and is particularly useful for examining the liver and other abdominal organs. The technician moves a handheld device over the skin, and the sound waves bounce off internal structures to create pictures on a screen. Ultrasound is painless and doesn’t use radiation.^[2]

Laboratory Tests and Blood Work

Blood tests don’t directly show whether cancer has spread, but they provide important clues about organ function and overall health. When breast cancer metastasizes to organs like the liver, blood tests may reveal abnormal levels of certain enzymes or other substances that indicate the organ isn’t working properly. Tumor markers are substances that cancer cells release into the bloodstream, and elevated levels of certain markers may suggest cancer activity, though these tests alone cannot confirm metastatic disease.^[10]

Some newer blood tests look for circulating tumor cells or pieces of tumor DNA in the bloodstream, but these are not yet standard practice for diagnosing metastatic breast cancer. Research in this area continues to advance.^[7]

Physical Examination and Medical History

A thorough physical examination and detailed review of symptoms and medical history form the foundation of diagnosis. Doctors check for signs like enlarged lymph nodes, tenderness over bones, abnormal breath sounds, or changes in the size or appearance of the liver. They also ask about specific symptoms that might point to metastases in particular organs, such as headaches and vision changes (brain), bone pain and fractures (bones), shortness of breath and persistent cough (lungs), or abdominal pain and jaundice (liver).^[2]^[10]

Specialized Tests for Specific Sites

When doctors need to examine specific areas more closely, they may use additional procedures. Endoscopy involves inserting a thin tube with a camera through the mouth or another opening to look directly at internal organs. Pleural fluid sampling (also called thoracentesis) removes fluid that has accumulated around the lungs so it can be tested for cancer cells. These procedures help confirm whether cancer has spread to particular locations.^[10]

⚠️ Important

If you have a long period between your original breast cancer diagnosis and new symptoms, a biopsy becomes even more important. This helps rule out benign processes that can look like cancer on imaging tests and confirms whether any new problem is actually related to breast cancer. The biopsy tissue can also reveal whether the cancer’s characteristics have changed, which influences treatment choices.^[10]

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or new combinations of existing treatments for metastatic breast cancer. Many people with advanced breast cancer consider joining clinical trials as a way to access cutting-edge therapies that aren’t yet widely available. However, each clinical trial has specific requirements, called eligibility criteria, that determine who can participate. Meeting these criteria requires undergoing certain diagnostic tests.^[8]

Standard Baseline Testing

Before enrolling in a clinical trial, patients typically need a comprehensive set of baseline tests to document their current condition. These tests establish a starting point that researchers will use to measure whether the experimental treatment is working. Baseline testing usually includes imaging scans of all known metastatic sites using CT, MRI, PET, or bone scans. These images show the size and location of tumors before treatment begins.^[10]

Blood work forms another essential component of clinical trial screening. Trials often require specific blood tests to check liver function, kidney function, blood cell counts, and general health markers. Some trials exclude people whose organs aren’t functioning well enough to handle the experimental treatment safely. Blood tests may also measure tumor markers or look for specific genetic mutations that the trial is targeting.^[10]

Molecular and Genetic Testing

Many modern clinical trials for metastatic breast cancer focus on treatments that target specific characteristics of cancer cells. For this reason, extensive molecular and genetic testing of tumor tissue has become a standard requirement for trial enrollment. Biomarker testing, also called genomic testing or next-generation sequencing, examines the genetic makeup of cancer cells to identify specific mutations or abnormalities that might respond to targeted therapies.^[17]

This testing requires a fresh biopsy sample or archived tissue from a previous biopsy or surgery. The laboratory analyzes the DNA of the cancer cells looking for specific changes. For example, some trials only accept patients whose tumors have mutations in genes called BRCA1 or BRCA2, while others look for alterations in pathways involving PIK3CA, AKT, or mTOR. The presence or absence of certain biomarkers determines whether a patient qualifies for particular trials.^[17]

Testing for hormone receptor status and HER2 status remains critical because many trials specifically target hormone receptor-positive, hormone receptor-negative, HER2-positive, or HER2-negative breast cancer. Some trials focus on triple-negative breast cancer, which lacks hormone receptors and doesn’t overexpress HER2. Patients need current test results showing their tumor’s receptor status to determine which trials they might qualify for.^[12]

Performance Status and Organ Function Assessment

Clinical trials evaluate patients’ overall health and ability to tolerate treatment using measures called performance status scales. While not strictly diagnostic tests, these assessments help researchers determine whether someone is healthy enough for a trial. Doctors assess how well patients can carry out daily activities and care for themselves.

Detailed tests of organ function help trials exclude patients who might be harmed by experimental treatments. For instance, heart function tests like echocardiograms or electrocardiograms (EKGs) may be required before trials involving drugs that could affect the heart. Pulmonary function tests assess lung capacity and breathing ability. These tests protect patient safety while ensuring that trial results reflect the treatment’s effects rather than pre-existing health problems.^[10]

Documentation of Disease Extent

Clinical trials need precise documentation of where metastases are located and how much disease is present. This typically requires systematic imaging of common metastatic sites including bones, lungs, liver, and brain. Some trials only accept patients with a certain number of metastatic sites or a particular pattern of spread. Others specifically seek patients whose cancer has spread to particular organs to test treatments designed for those locations.^[10]

Previous Treatment History

While not a diagnostic test in the traditional sense, documenting previous treatments is crucial for clinical trial qualification. Trials often specify that patients must have received (or not received) certain prior therapies. Patients need detailed medical records showing what treatments they’ve had, how long they received them, and how the cancer responded. This helps ensure that trial participants have similar treatment backgrounds, making the research results more reliable.^[8]

Monitoring Tests During Trials

Once enrolled in a clinical trial, patients undergo regular diagnostic tests to monitor how well the treatment is working and watch for side effects. These typically include repeated imaging scans every few months to measure changes in tumor size, regular blood tests to check organ function and side effects, and assessment of symptoms. The frequency and type of monitoring depend on the specific trial protocol.^[8]

Understanding the diagnostic requirements for clinical trials helps patients and their doctors decide whether trial participation makes sense. While the testing can be extensive, it ensures that experimental treatments are studied in appropriate patient populations and that participants receive careful monitoring for both benefits and risks.

Prognosis and Survival Rate

Prognosis

The outlook for people with metastatic breast cancer varies considerably from person to person. Some individuals have rapidly progressing disease that spreads to multiple vital organs and causes serious problems within months. Others experience a much slower disease course, with cancer that responds well to treatment and remains stable for extended periods. Between these extremes exists a wide range of individual experiences.^[10]

Several factors influence how metastatic breast cancer progresses. The location where cancer has spread plays an important role: people with metastases only in soft tissues, lymph nodes, or bones often have better outcomes than those with cancer in vital organs like the liver, lungs, or brain. The biological characteristics of the tumor matter significantly as well. Cancers that have hormone receptors (estrogen or progesterone receptors) tend to respond better to hormone-blocking treatments and generally progress more slowly than hormone receptor-negative tumors.^[10]

The speed at which the tumor grows and its sensitivity to available treatments substantially affect prognosis. Some metastatic breast cancers respond dramatically to treatment, shrinking significantly or even becoming undetectable on scans. People who achieve what doctors call a complete remission, where no cancer can be detected, may remain free of detectable disease for years, though the cancer is still considered present and treatment typically continues.^[10]

The treatment history also influences outcomes. People receiving their first treatment for metastatic disease often respond better than those whose cancer has already been treated with multiple lines of therapy. However, thanks to ongoing research and new drug development, doctors now have more treatment options than ever before. If one treatment stops working, others are usually available to try.^[8]

While metastatic breast cancer currently has no cure, more people are living longer with the disease than in the past. New targeted therapies, improved hormone treatments, better chemotherapy regimens, and advances in supportive care have all contributed to extending life and improving quality of life. Some people with metastatic breast cancer live productively for many years, with the disease managed as a chronic condition rather than immediately life-threatening.^[2]^[4]

Survival Rate

Understanding survival statistics for metastatic breast cancer requires recognizing their limitations. The median survival for people with metastatic breast cancer is generally reported as 2 to 3 years, meaning half of patients live longer than this timeframe and half live shorter periods. However, these numbers come from data collected several years ago and don’t reflect the impact of newer treatments that have recently become available.^[10]

Recent estimates suggest that around 170,000 to 200,000 women in the United States are currently living with metastatic breast cancer. About 20% to 30% of women initially diagnosed with early-stage breast cancer eventually develop metastatic disease at some point in their lives. Additionally, approximately 6% to 10% of women receive a metastatic breast cancer diagnosis when they are first diagnosed with breast cancer.^[2]^[7]

Survival rates vary significantly based on the characteristics of the cancer and where it has spread. People with hormone receptor-positive tumors generally have longer survival times than those with hormone receptor-negative cancers. Similarly, those with metastases limited to bones or soft tissues typically survive longer than people with liver, lung, or brain involvement. The volume of disease also matters: individuals with small amounts of cancer in one or two locations often do better than those with extensive spread to multiple organs.^[10]

It’s crucial to understand that survival statistics describe large groups of people and cannot predict what will happen to any individual person. Many factors influence outcomes, including the specific characteristics of the cancer, overall health, response to treatment, and access to newer therapies. Some people with metastatic breast cancer survive for 10 years or longer, especially those who respond well to treatment. A small percentage who achieve complete remission after treatment remain progression-free for extended periods, occasionally exceeding 20 years.^[10]

Recent research indicates that outcomes are improving. Data published in 2017 showed that about 16% of patients with HER2-positive metastatic breast cancer were surviving with undetectable levels of cancer for many years after treatment. Because cancer registry databases typically run several years behind current practice, and because new treatments continue to be approved, actual survival rates for people diagnosed today are likely better than older published statistics suggest.^[14]^[17]

Despite these improvements, metastatic breast cancer remains the cause of approximately 90% of breast cancer deaths. This underscores the critical need for continued research into new treatments and better understanding of the disease. However, the trend toward longer survival times and improved quality of life offers genuine hope for people living with metastatic breast cancer today.^[6]